{"filing":{"accession_number":"0001339970-26-000065","cik":"0001339970","ticker":"ATYR","company_name":"aTYR PHARMA INC","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"atyr-20260924.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000065/atyr-20260924.htm"},"events":[{"id":34737,"run_id":31983,"accession_number":"0001339970-26-000065","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"aTyr Pharma announced FDA alignment on the protocol for a Phase 3 clinical trial of efzofitimod in pulmonary sarcoidosis, with plans to initiate study activities in Q4 2026. This is a material operational and regulatory milestone for a clinical-stage biopharmaceutical company—it represents significant progress in the development pathway for the company's lead therapeutic candidate and signals FDA acceptance of the trial design. While not a specific named event type, this clearly falls within operational/strategic business development rather than financial, governance, legal, or existential categories.","company_name":"aTYR PHARMA INC","ticker":"ATYR","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38566,"accession_number":"0001339970-26-000065","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"aTyr Pharma announced FDA alignment on the protocol for a Phase 3 clinical trial of efzofitimod in pulmonary sarcoidosis, with plans to initiate study activities in Q4 2026. This is a material operational and regulatory milestone for a clinical-stage biopharmaceutical company—it represents significant progress in the development pathway for the company's lead therapeutic candidate and signals FDA acceptance of the trial design. While not a specific named event type, this clearly falls within operational/strategic business development rather than financial, governance, legal, or existential categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:01:39.992611+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38566,"accession_number":"0001339970-26-000065","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"aTyr Pharma announced FDA alignment on the protocol for a Phase 3 clinical trial of efzofitimod in pulmonary sarcoidosis, with plans to initiate study activities in Q4 2026. This is a material operational and regulatory milestone for a clinical-stage biopharmaceutical company—it represents significant progress in the development pathway for the company's lead therapeutic candidate and signals FDA acceptance of the trial design. While not a specific named event type, this clearly falls within operational/strategic business development rather than financial, governance, legal, or existential categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:01:39.992611+00:00","company_name":"aTYR PHARMA INC","ticker":"ATYR","filing_date":"2026-09-24"}]}